Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of Afimkibart also known as RO7790121 in adults with moderate to severe rheumatoid arthritis RA who have not responded well or cannot tolerate tumor necrosis factor TNF andor Janus kinase JAK inhibitors. This Phase II, multicenter, randomized, double-blind, placebo-controlled study aims to compare Afimkibart with placebo in this group to better understand its impact on disease activity. Participants will receive either Afimkibart or a placebo through subcutaneous under the skin injections. The study includes two experimental groups receiving Afimkibart and one placebo group, all administered by injection. Treatment and assessments occur over several weeks, with key evaluations at Week 14 and Week 24 to measure changes in disease activity and response. During the study, participants will undergo various assessments including joint counts, patient and physician global assessments, laboratory tests for inflammation markers, and questionnaires on health status and pain. The main outcome is the change in Disease Activity Score-28 for Rheumatoid Arthritis with C-Reactive Protein DAS28-CRP at Week 14. Safety will be monitored throughout the trial up to Week 38, including tracking adverse events and immune responses to the drug. Participants can expect regular visits for injections and evaluations during this period.
Actively Recruiting
Researchers are evaluating the long-term safety and effectiveness of Afimkibart also called RO7790121 in adults with moderate to severe Rheumatoid Arthritis who have not responded well or are intolerant to tumor necrosis factor TNF andor Janus kinase JAK inhibitors. This study focuses on participants who have already been treated with Afimkibart in earlier clinical trials. The goal is to understand how Afimkibart works over an extended period in this patient group. Participants will receive Afimkibart as a subcutaneous injection according to the study protocol. The study uses a randomized, parallel design with two experimental groups both receiving Afimkibart. The treatment lasts up to six years, allowing researchers to gather long-term data on safety and disease control. There are no placebo or comparator groups in this extension study. During the study, participants will be regularly assessed for adverse events and improvements in Rheumatoid Arthritis symptoms using measures like the American College of Rheumatology improvement criteria and Disease Activity Scores. Blood tests will monitor Afimkibart levels and antibody responses. The study also tracks clinical remission and low disease activity over time. Participants are monitored closely throughout the study to evaluate treatment effects and safety for up to six years.
Actively Recruiting
Researchers are evaluating sarilumab, given at two different doses, for treating adults aged 50 years and older with early polymyalgia rheumatica PMR. This randomized, double-blind, placebo-controlled Phase 3 study aims to compare the effectiveness of sarilumab plus a 52-week prednisone taper against placebo plus the same prednisone taper. The purpose is to assess whether sarilumab can improve sustained remission rates and to determine its safety and tolerability in this population. Participants are assigned to one of three groups placebo with prednisone taper, sarilumab 150 mg every two weeks with prednisone taper, or sarilumab 200 mg every two weeks with prednisone taper. The prednisone taper lasts 52 weeks. The study includes an initial screening visit, baseline and randomization visit with first drug administration, multiple treatment visits every two weeks from Week 2 to Week 44, an end of treatment visit at Week 52, and a final study visit at Week 58. During the study, participants will undergo regular assessments including monitoring for remission status, flare rates, and changes in PMR activity scores. Safety will be evaluated by tracking adverse events, laboratory values, and antibody formation against the drug throughout the study period up to Week 58. Participants may also complete quality of life questionnaires during the study. The total participation time spans approximately 58 weeks.